During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on how recent trial data and sites of ...

The SunRISe-2 trial evaluating TAR-200 combined with cetrelimab vs chemoradiation in muscle-invasive bladder cancer has been ...

The first patient in a phase 1/2 trial investigating a novel agent for the treatment of non–small cell lung cancer has been ...

The FDA has granted VLS-1488 fast track designation in patients with platinum-resistant high-grade serous ovarian cancer.

The KEYNOTE-689 study evaluating pembrolizumab in this patient population met its primary end point of event-free survival.

Ana Baramidze, MD, PhD, discussed 5-year follow-up results from the EMPOWER-Lung study evaluating cemiplimab vs chemotherapy ...

Erika P. Hamilton, MD, discusses the patient population with breast cancer enrolled in the TROPION-PanTumor01 trial in relation to the efficacy of datopotamab deruxtecan.

David Braun, MD, PhD, discusses how biomarkers are evolving for the treatment of renal cell carcinoma. Biomarkers play a crucial role in the management of renal cell carcinoma (RCC). These biological ...

Jaime Merchan, MD, discusses what the potential clinical implications or takeaways for colleagues are based on findings from ...

A new study suggests that patients with multiple myeloma who achieve sustained MRD-negativity for at least three years may be ...

The CHRYSALIS-2 study (NCT04077463) evaluated the combination of amivantamab (Rybrevant), an EGFR-MET bispecific antibody, ...

Panelists discuss how considerations for treatment approach encompass patient-specific factors, treatment modalities, and the integration of emerging therapies to optimize outcomes in clinical ...